Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Brian M. G. Janssen"'
Autor:
Marloes A. Wijdeven, Remon van Geel, Jorin H. Hoogenboom, Jorge M. M. Verkade, Brian M. G. Janssen, Inge Hurkmans, Laureen de Bever, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™
Externí odkaz:
https://doaj.org/article/848d309b246a42aca0115d74462db631
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 6, Pp 12631-12647 (2015)
The advancement of DNA-based bionanotechnology requires efficient strategies to functionalize DNA nanostructures in a specific manner with other biomolecules, most importantly peptides and proteins. Common DNA-functionalization methods rely on labori
Externí odkaz:
https://doaj.org/article/5ad68707bfa040518dca63d7e9b7cfa4
Autor:
Jorge M. M. Verkade, Marloes A. Wijdeven, Remon van Geel, Brian M. G. Janssen, Sander S. van Berkel, Floris L. van Delft, Antibodies Editorial Office
Publikováno v:
Antibodies, Vol 7, Iss 3, p 34 (2018)
The conflict of interest section of the published paper [1] has been updated as follows[...]
Externí odkaz:
https://doaj.org/article/fb2f870787b6466e95da8a6ea1543a7a
Autor:
Jorge M. M. Verkade, Marloes A. Wijdeven, Remon van Geel, Brian M. G. Janssen, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
Antibodies, Vol 7, Iss 1, p 12 (2018)
Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with littl
Externí odkaz:
https://doaj.org/article/3467b0204f6846e79773a9ba2403fa4a